Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study
In this large French observational study, T-DXd users were older, had more comorbidities, and had more brain metastases than patients included in registration trials. The rapid expansion of clinical indications of T-DXd calls for proactive surveillance and timely management of potentially life-threatening T-DXd-related toxicity.
Authors
- A. Di Meglio
- Nadia Haddy (ORCID: https://orcid.org/0000-0001-9316-8280)
- Imène Mansouri (ORCID: https://orcid.org/0000-0001-6811-8695)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Hugo Jourdain (ORCID: https://orcid.org/0000-0001-8035-7517)
- David Desplas (ORCID: https://orcid.org/0000-0003-1151-3867)
Institutions
- Inserm (FR)
- Institut Gustave Roussy (FR)
- National Health Insurance Fund (RS)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104083
- Citations
- 12
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.11